Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 1, 2009, Pages 17-24

  Weinberg, Adriana ^a,g   Huang, Sharon ^b   Fenton, Terence ^b   Patterson Bartlett, Julie ^a   Gona, Philimon ^c   Read, Jennifer S ^d   Dankner, Wayne M ^e   Nachman, Sharon ^f  

^a Children's Hospital Colorado   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c Boston University   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e DUKE UNIVERSITY   (United States)

^f STONY BROOK UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

Antibody titers; B cell phenotype; Cell mediated immunity; Hepatitis A virus vaccine; HIV; T cell phenotype

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; HEPATITIS A VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; FEMALE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; VIREMIA; VIRUS LOAD;

ADOLESCENT; ANTIBODY FORMATION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HIV INFECTIONS; HUMANS; MALE; MULTIVARIATE ANALYSIS; VACCINATION; YOUNG ADULT;

EID: 69549131060     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b011f6     Document Type: Article

References (41)

1. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2006;25:920-929.
2. Hess G, Clemens R, Bienzle U, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol. 1995;46:40-42.
3. Kemper CA, Haubrich R, Frank I, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis. 2003;187:1327-1331. (Pubitemid 36438975)
4. Mount AM, Mwapasa V, Elliott SR, et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet. 2004;363:1860-1867. (Pubitemid 38748641)
5. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis Avaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis. 1997;176:1064-1067. (Pubitemid 27411052)
6. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2003;37:438-447. (Pubitemid 36976504)
7. Santagostino E, Gringeri A, Rocino A, et al. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost. 1994;72:508-510. (Pubitemid 24305640)
8. Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis. 2004;39:1207-1213. (Pubitemid 40169321)
9. Rigaud M, Borkowsky W, Muresan P, et al. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis. 2008;198:1123-1130.
10. Jiang W, Lederman MM, Mohner RJ, et al. Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol. 2008;82:7837-7845.
11. Qiao X, He B, Chiu A, et al. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol. 2006;7:302-310.
12. Viau M, Veas F, Zouali M. Direct impact of inactivated HIV-1 virions on B lymphocyte subsets. Mol Immunol. 2007;44:2124-2134. (Pubitemid 44827262)
13. De Milito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood. 2004;103:2180-2186. (Pubitemid 38326236)
14. Moir S, Ogwaro KM, Malaspina A, et al. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A. 2003;100:6057-6062. (Pubitemid 36576930)
15. De Milito A, Morch C, Sonnerborg A, et al. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS. 2001;15:957-964. (Pubitemid 32476662)
16. Hart M, Steel A, Clark SA, et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol. 2007;178:8212-8220. (Pubitemid 46898094)
17. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205:1797-1805.
18. Moir S, Malaspina A, Pickeral OK, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med. 2004;200:587-599. (Pubitemid 39258308)
19. Morrow M, Valentin A, Little R, et al. A splenic marginal zone-like peripheral blood CD27+B220- B cell population is preferentially depleted in HIV type 1-infected individuals. AIDS Res Hum Retroviruses. 2008;24:621-633. (Pubitemid 351571037)
20. Titanji K, De Milito A, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood. 2006;108:1580-1587. (Pubitemid 44316125)
21. Berberian L, Valles-Ayoub Y, Sun N, et al. AVH clonal deficit in human immunodeficiency virus-positive individuals reflects a B-cell maturational arrest. Blood. 1991;78:175-179.
22. Ho J, Moir S, Malaspina A, et al. Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. Proc Natl Acad Sci U S A. 2006;103:19436-19441. (Pubitemid 46026049)
23. Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A. 2006;103:2262-2267. (Pubitemid 43271658)
24. Moir S, Malaspina A, Ogwaro KM, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A. 2001;98:10362-10367. (Pubitemid 32803025)
25. D'Orsogna LJ, Krueger RG, McKinnon EJ, et al. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS. 2007;21:1747-1752.
26. Moir S, Malaspina A, Ho J, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis. 2008;197:572-579. (Pubitemid 351321535)
27. Chen MY, Hung CC, Fang CT, et al. Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy. Clin Infect Dis. 2001;32:1361-1365.
28. Deayton JR, Sabin CA, Britt WB, et al. Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. AIDS. 2002;16:2129-2135.
29. Resino S, Galan I, Perez A, et al. HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol. 2004;137:570-577. (Pubitemid 39128085)
30. Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis. 2006;193:302-311. (Pubitemid 43113494)
31. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48:1-37.
32. Horng YC, Chang MH, Lee CY, et al. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J. 1993;12:359-362. (Pubitemid 23150795)
33. Sandman L, Davidson M, Krugman S. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. J Infect Dis. 1995;171(Suppl 1):S50-S52.
34. Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol. 1994;44:446-451.
35. Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol. 1996;49:235-241.
36. Launay O, Grabar S, Gordien E, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr. 2008;49:272-275.
37. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305-310. (Pubitemid 32721722)
38. Levin MJ, Song LY, Fenton T, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008;26:4210-4217.
39. Overton ET, Sungkanuparph S, Powderly WG, et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005;41:1045-1048. (Pubitemid 41368231)
40. Jacobsen MC, Thiebaut R, Fisher C, et al. Pediatric human immunodeficiency virus infection and circulating IgD+ memory B cells. J Infect Dis. 2008;198:481-485.
41. Schmidtke P, Habermehl P, Knuf M, et al. Cell mediated and antibody immune response to inactivated hepatitis A vaccine. Vaccine. 2005;23:5127-5132. (Pubitemid 41356542)